Gérald Voss

6.5k total citations · 1 hit paper
75 papers, 4.3k citations indexed

About

Gérald Voss is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, Gérald Voss has authored 75 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Virology, 37 papers in Immunology and 21 papers in Infectious Diseases. Recurrent topics in Gérald Voss's work include HIV Research and Treatment (49 papers), Immune Cell Function and Interaction (27 papers) and vaccines and immunoinformatics approaches (13 papers). Gérald Voss is often cited by papers focused on HIV Research and Treatment (49 papers), Immune Cell Function and Interaction (27 papers) and vaccines and immunoinformatics approaches (13 papers). Gérald Voss collaborates with scholars based in United States, Belgium and United Kingdom. Gérald Voss's co-authors include Kent E. Kester, John R. Mascola, Norman L. Letvin, David C. Montefiori, Joe Cohen, Marguerite Koutsoukos, Nadia Tornieporth, Paul A. Goepfert, Martine Delchambre and Jesus F. Salazar-Gonzalez and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Gérald Voss

73 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

2005 845 citations John R. Mascola, Marguerite Koutsoukos et al. Journal of Virology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gérald Voss United States	31	2.5k	2.1k	1.2k	1.2k	1.1k	75	4.3k
Yaming Cao United States	21	4.3k 1.7×	2.5k 1.2×	2.0k 1.7×	404 0.3×	653 0.6×	34	5.0k
Robert T. Bailer United States	42	2.7k 1.1×	2.5k 1.2×	2.5k 2.1×	488 0.4×	1.4k 1.3×	79	5.9k
Sanjay Gurunathan United States	28	785 0.3×	1.9k 0.9×	1.0k 0.9×	932 0.8×	1.1k 0.9×	46	4.4k
Jean‐Louis Excler United States	31	1.4k 0.6×	932 0.4×	1.2k 1.0×	364 0.3×	721 0.6×	116	3.0k
Shan Lu United States	40	1.9k 0.8×	2.4k 1.2×	1.7k 1.4×	240 0.2×	1.6k 1.4×	168	5.3k
Bruno Guy France	36	871 0.4×	1.2k 0.6×	2.1k 1.7×	1.9k 1.6×	631 0.6×	72	4.2k
Joe Cohen United States	36	681 0.3×	1.8k 0.9×	862 0.7×	2.6k 2.2×	1.6k 1.4×	55	4.8k
Martha Sedegah United States	35	743 0.3×	2.4k 1.2×	709 0.6×	2.8k 2.4×	2.1k 1.8×	106	5.2k
Shixia Wang United States	37	1.2k 0.5×	1.9k 0.9×	1.2k 1.0×	159 0.1×	1.4k 1.2×	138	4.2k
Kent E. Kester United States	34	635 0.3×	1.6k 0.8×	769 0.6×	2.8k 2.4×	1.8k 1.5×	54	4.7k

Countries citing papers authored by Gérald Voss

Since Specialization

Citations

This map shows the geographic impact of Gérald Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gérald Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gérald Voss more than expected).

Fields of papers citing papers by Gérald Voss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gérald Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gérald Voss. The network helps show where Gérald Voss may publish in the future.

Co-authorship network of co-authors of Gérald Voss

This figure shows the co-authorship network connecting the top 25 collaborators of Gérald Voss. A scholar is included among the top collaborators of Gérald Voss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gérald Voss. Gérald Voss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cutland, Clare, Mercedes Bonet, Ángela Gentile, et al.. (2024). Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 43(Pt 1). 126479–126479. 3 indexed citations

Clark, Rebecca A., Rupali J. Limaye, Birgitte Giersing, et al.. (2024). Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report. LSHTM Research Online (London School of Hygiene and Tropical Medicine). 2. 1 indexed citations

Muñoz, Flor M., Clare Cutland, Christine E. Jones, et al.. (2022). Preparing for Disease X: Ensuring Vaccine Equity for Pregnant Women in Future Pandemics. Frontiers in Medicine. 9. 893292–893292. 4 indexed citations

Voss, Gérald, Jeanne‐Marie Jacquet, Nadia Tornieporth, et al.. (2021). Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12–13 February 2020. Vaccine. 39(51). 7357–7362. 8 indexed citations

Williams, Ann, Bernard Fritzell, Dominick J. Laddy, et al.. (2020). The TB vaccine development pathway – An innovative approach to accelerating global TB vaccine development. Tuberculosis. 126. 102040–102040. 8 indexed citations

Lorin, Clarisse, Yannick Vanloubbeeck, Marguerite Koutsoukos, et al.. (2015). Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques. PLoS ONE. 10(4). e0122835–e0122835. 9 indexed citations

Page, Mark, Richard Stebbings, Neil Berry, et al.. (2012). Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Retrovirology. 9(1). 56–56. 4 indexed citations

Mörner, Andreas, Iyadh Douagi, Mattias N.E. Forsell, et al.. (2008). Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. Journal of Virology. 83(2). 540–551. 49 indexed citations

Goepfert, Paul A., Georgia D. Tomaras, Helen Horton, et al.. (2006). Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 25(3). 510–518. 71 indexed citations

10.

Sun, Peifang, Robert Schwenk, Katherine White, et al.. (2003). Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ. The Journal of Immunology. 171(12). 6961–6967. 183 indexed citations

11.

Zhang, Ying, M Huber, Benedikt Weißbrich, et al.. (2001). Characterization of HIV-Specific Proliferative T Cell Responses in HIV-Infected Persons. AIDS Research and Human Retroviruses. 17(7). 623–629. 5 indexed citations

12.

Chen, Zheng W., Abie Craiu, Ling Shen, et al.. (2000). Simian Immunodeficiency Virus Evades a Dominant Epitope-Specific Cytotoxic T Lymphocyte Response Through a Mutation Resulting in the Accelerated Dissociation of Viral Peptide and MHC Class I. The Journal of Immunology. 164(12). 6474–6479. 60 indexed citations

13.

Doherty, J.F., M Pinder, Nadia Tornieporth, et al.. (1999). A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.. American Journal of Tropical Medicine and Hygiene. 61(6). 865–868. 66 indexed citations

14.

Lüke, Wolfgang, Cheick Coulibaly, Ulf Dittmer, et al.. (1996). Simian Immunodeficiency Virus (SIV) gp130 Oligomers Protect Rhesus Macaques (Macaca mulatta) against the Infection with SIVmac32H Grown on T-Cells or Derivedex Vivo. Virology. 216(2). 444–450. 19 indexed citations

15.

Dittmer, Ulf, et al.. (1994). Comparison of humoral immunity and induction of proliferating T lymphocytes in vaccinia virus-infected rabbits and rhesus macaques. American Journal of Veterinary Research. 55(9). 1250–1255. 5 indexed citations

16.

Stahl‐Hennig, Christiane, Cheick Coulibaly, Harald Petry, et al.. (1994). Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.. PubMed. 10 Suppl 2. S27–32. 7 indexed citations

17.

Lüke, Wolfgang, Gérald Voss, Christiane Stahl‐Hennig, et al.. (1993). Protection of Cynomolgus Macaques ( Macaca fascicularis ) Against Infection with the Human Immunodeficiency Virus Type 2 Strain ben (HIV-2ben) by Immunization with the Virion-Derived Envelope Glycoprotein gp130. AIDS Research and Human Retroviruses. 9(5). 387–394. 16 indexed citations

18.

Voss, Gérald, Christiane Stahl‐Hennig, Harald Petry, et al.. (1992). Immunization of Rhesus Monkeys with High- and Low-Dose Tween-Ether-Disrupted SIV _MAC. AIDS Research and Human Retroviruses. 8(8). 1397–1400. 9 indexed citations

19.

Voss, Gérald, et al.. (1992). Virus-specific cytotoxic T-lymphocytes in HIV-2-infected cynomolgus macaques. AIDS. 6(10). 1077–1084. 6 indexed citations

20.

Voss, Gérald, et al.. (1992). Morphogenesis of recombinant HIV-2 gag core particles. Virus Research. 24(2). 197–210. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact